BofA/Merrill Lynch Upgrades Orexigen Therapeutics (OREX) to Buy
Tweet
Share
E-mail
Get Alerts OREX Hot Sheet
Price: $0.22 --0%
Rating Summary:
3 Buy, 7 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 11 | New: 26
Rating Summary:
3 Buy, 7 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 11 | New: 26
Join SI Premium – FREE
BofA/Merrill Lynch upgraded Orexigen Therapeutics (NASDAQ: OREX) from Netural to Buy and raised their price target from $3 to $5.
For more ratings news on Orexigen Therapeutics click here and for the rating history of Orexigen Therapeutics click here.
Shares of Orexigen Therapeutics closed at $2.92 yesterday.
For more ratings news on Orexigen Therapeutics click here and for the rating history of Orexigen Therapeutics click here.
Shares of Orexigen Therapeutics closed at $2.92 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Upgrades Americold Realty Trust (COLD) to Neutral
- BofA Securities Reiterates Buy Rating on NVIDIA (NVDA)
- BofA raises hyperscaler AI capex outlook to $3.6tn through 2028
Create E-mail Alert Related Categories
Hot Upgrades, UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
